Comparison study of Puregon® and Elonva® used in a long gonadotropin-releasing hormone (GnRH) agonist protocol for IVF stimulation

Randomised controlled trial comparing Puregon® and Elonva® both in a GnRH agonist protocol for IVF stimulation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN98623456

Enrollment

160

Registered

2012-03-27

Start date

2012-03-01

Completion date

Unknown

Last updated

2019-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Female infertility Urological and Genital Diseases Female infertility

Interventions

Both groups: Decapeptyl® SR, between day 21 and day 25 of the cycle. Ultrasound control after 2 weeks. Group 1: Start of Puregon® on day of scan. Ultrasound and blood test after 5 day

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Second IVF attempt 2. Younger than 40 years 3. Anti-mullerian hormone less than 3

Exclusion criteria

Exclusion criteria: 1. Previous cycle ovarian hyper stimulation syndrome 2. Pre-implantation genetic diagnosis cycles 3. IVF cycles using testicular sperm biopsy 4. Patients needing more than 2500 U of gonadotropins in the first cycle 5. Patients above 40 years

Design outcomes

Primary

Measure	Time frame
Pregnancy rate	—

Secondary

Measure	Time frame
1. Days of stimulation needed 2. Doses of gonadotropins used 3. Number of oocytes retrieved 4. Fertilization rate 5. Number of embryos for cryopreservation	—

Countries

Belgium

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026